| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 6 Jun 2024 | 6 Jun 2024 |
| Please find our intimation on the captioned subject. | ||
| Board Meeting | 14 May 2024 | 3 May 2024 |
| THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2024 inter alia to consider and approve Please refer our intimation on the captioned subject. 1) Approval of the Financial Results for the FY 2023-24 2) Final Dividend for the FY 2023-24 (As Per BSE Announcement Dated on: 14/05/2024) | ||
| Board Meeting | 10 Feb 2024 | 29 Jan 2024 |
| THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 inter alia to consider and approve Un-audited Standalone and Consolidated Financial Results for the quarter ended 31st December 2023. Please refer our attached intimation (As per BSE Announcement Dated on 10/02/2024) | ||
| Board Meeting | 4 Nov 2023 | 25 Oct 2023 |
| THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2023 inter alia to consider and approve the Un-audited Standalone and Consolidated Financial Results for the quarter and half year ended on 30th September 2023. Further in continuation of our Letter dated 28th September 2023 the Trading Window in respect of dealing in the Companys Securities was closed for all Directors / Designated Employees from the opening of the trading hours on Sunday 1st October 2023 which shall remain closed till the closure of trading hours on 6th November 2023 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time. Pursuant to Regulation 30 of the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its meeting held today i.e. on Saturday, 4th November, 2023, has inter-alia approved the following: a) The Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year ended 30th September, 2023. A copy of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year ended 30th September, 2023 together with Limited Review Report issued by M/s. Krishaan & Co., Chartered Accountants is enclosed herewith. b) The proposal to enter into Master Service Agreement with its Related Party and Associate Company, viz. Gujarat Themis Biosyn Limited. The details required as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 read with Regulation 30A of the Listing Regulations are enclosed as Annexure - I. This may be taken as compliance under the Listing Regulations. Please find enclosed financial results for the quarter and half-year ended 30th September 2023 (As Per BSE Announcement Dated on 04.11.2023) | ||
| Board Meeting | 7 Sep 2023 | 7 Sep 2023 |
| We would like to inform that Board of Directors of the Company has approved and passed resolutions (as mentioned in the attached intimation) by circulation on September 7, 2023. Kindly take the above intimation on record. | ||
| Board Meeting | 10 Aug 2023 | 2 Aug 2023 |
| THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2023 inter alia to consider and approve With respect to the captioned subject please be informed that a meeting of the Board of Directors of Themis Medicare Limited is scheduled to be held on Saturday 12th August 2023 inter alia to consider and approve the Un-audited Standalone and Consolidated Financial Results for the Quarter ended on 30th June 2023. Further in continuation of our Letter dated 27th June 2023 the Trading Window in respect of dealing in the Companys Securities was closed for all Directors/Designated Employees from the opening of the trading hours on Saturday 1st July 2023 which shall remain closed till the closure of trading hours on Monday 14th August 2023 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading (the Code) adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time. This is for your information and record. THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 ,inter alia, to consider and approve This has reference to our letter dated 02nd August, 2023 informing that a meeting of the Board of Directors of Themis Medicare Limited (the Company) to be held on Saturday, 12th August, 2023 inter alia, to consider and approve the Un-audited Standalone Financial Results for the Quarter ended on 30th June, 2023. The said meeting is now preponed and rescheduled and will now be held on Thursday, 10th August,2023. (As per BSE Announcement Dated on 03/08/2023) Pursuant to Regulation 30 of the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its meeting held today i.e. on Thursday, August 10, 2023, has inter-alia approved the following: a) The Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th June, 2023. A copy of Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th June, 2023 together with Limited Review Report issued by M/s. Krishaan & Co., Chartered Accountants is enclosed herewith. b) Incorporation of a subsidiary company in India as private limited company. This may be taken as compliance under the Listing Regulations. Please find attached unaudited results for the quarter ended June 30, 2023 (Standalone and Consolidated) (As Per BSE Announcement dated on 10.08.2023) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
